Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 4/20 | 0.31 |
| ▸ | F11 | P03951 | 4/20 | 0.31 |
| ▸ | F7 | P08709 | 4/20 | 0.31 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136998 | 0.87 | F10 (0.33) | F10F11F7PRKAB2PRKAG1 | |
| SCHEMBL2133524 | 0.87 | MAP2K4 (0.32) | MAP2K4F10F11F7PRKAB2 | |
| SCHEMBL2134826 | 0.86 | PRKAB2 (0.39) | F10F11F7PRKAB2PRKAG1 | |
| SCHEMBL2141232 | 0.84 | F10 (0.37) | F10F11F7 | |
| SCHEMBL2729727 | 0.77 | F7 (0.43) | F10F11F7 | |
| SCHEMBL2731367 | 0.75 | IKBKB (0.39) | F10F11F7 | |
| SCHEMBL11028638 | 0.75 | F11 (0.47) | F10F11F7 | |
| SCHEMBL2139410 | 0.71 | F10 (0.36) | F10F11F7 | |
| SCHEMBL2135149 | 0.69 | CTSD (0.35) | — | |
| SCHEMBL2133151 | 0.69 | PRKAB2 (0.36) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | MAP2K4 2699/4885F10 4686/4885F11 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.